Revealing the cost of Type II diabetes in Europe
Top Cited Papers
- 24 May 2002
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetologia
- Vol. 45 (1), S5-S12
- https://doi.org/10.1007/s00125-002-0858-x
Abstract
‘The Cost of Diabetes in Europe-Type II study’ is the first coordinated attempt to measure total healthcare costs of Type II (non-insulin-dependent) diabetes mellitus in Europe. The study evaluated more than 7000 patients with Type II diabetes in eight countries — Belgium, France, Germany, Italy, the Netherlands, Spain, Sweden and the United Kingdom. A bottom-up, prevalence-based design was used, which optimised the collection of data at the national level while maintaining maximum international comparability. Effort was made to ensure consistency in terms of data specification, data collection tools and methods, sampling design, and the analysis and reporting of results. Results are reported for individual countries and in aggregate for the total study population. The total direct medical costs of Type II diabetes in the eight European countries was estimated at EUR 29 billion a year (1999 values). The estimated average yearly cost per patient was EUR 2834 a year. Of these costs, hospitalisations accounted for the greatest proportion (55%, range 30-65%) totalling EUR 15.9 billion for the eight countries. During the 6-month evaluation period, 13% of the Type II diabetic patients were hospitalised, with an average of 23 days in hospital projected annually. In contrast, drug costs for managing Type II diabetes were relatively low, with antidiabetic drugs and insulin accounting for only 7% of the total healthcare costs for Type II diabetes. Type II diabetes mellitus is a common disease and the prevalence is expected to increase considerably in the future, especially in developing countries. Current comprehensive economic data on the costs of diabetes are required for policy decisions to optimise resource allocation and to evaluate different approaches for disease management.This publication has 9 references indexed in Scilit:
- The Progressive Cost of Complications in Type 2 Diabetes MellitusArchives of Internal Medicine, 1999
- Incidence, prevalence, and mortality of diabetes in a large population. A report from the Skaraborg Diabetes Registry.Diabetes Care, 1999
- Diabetes: the cost of illness in SwedenJournal of Internal Medicine, 1998
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- The prevalence of diabetes mellitus in the Netherlands. A quantitative reviewEuropean Journal of Public Health, 1998
- Economic Consequences of Diabetes Mellitus in the U.S. in 1997Diabetes Care, 1998
- The Rising Global Burden of Diabetes and its Complications: Estimates and Projections to the Year 2010Diabetic Medicine, 1997
- Health care expenditures for people with diabetes mellitus, 1992.Journal of Clinical Endocrinology & Metabolism, 1994
- Diabetes—the Cost of Illness and the Cost of ControlActa Medica Scandinavica, 1983